Literature DB >> 23168308

Rhenium(I) tricarbonyl complexes of salicylaldehyde semicarbazones: synthesis, crystal structures and cytotoxicity.

Junming Ho1, Wan Yen Lee, Kelvin Jin Tai Koh, Peter Peng Foo Lee, Yaw-Kai Yan.   

Abstract

A series of N,N-disubstituted salicylaldehyde semicarbazones (SSCs), HOC(6)H(4)CHN-NHCONR(2), and their rhenium(I) tricarbonyl complexes, [ReBr(CO)(3)(SSC)], have been synthesised and characterised by IR and (1)H NMR spectroscopy. Crystallographic analysis of the complex [ReBr(CO)(3)(H(2)Bu(2))] (H(2)Bu(2)=SSC where R=Bu(n)) showed that the SSC acts as a bidentate ligand via its imino nitrogen and carbonyl oxygen atoms. The [ReBr(CO)(3)(SSC)] complexes exhibit moderate to high cytotoxicities towards MOLT-4 cells (IC(50)=1-24μM, cf. 18μM for cisplatin), and the majority of them are virtually non-toxic against non-cancerous human fibroblasts. Apoptotic assays of [ReBr(CO)(3)(H(2)Bnz(2))] (Bnz=benzyl) revealed that it mediates cytotoxicity in MOLT-4 cells via apoptosis. The complex [ReBr(CO)(3)(H(2)Bnz(2))] reacts with guanosine by proton transfer from the phenolic OH group to N(7) of guanosine. In (CD(3))(2)SO, [ReBr(CO)(3)(H(2)Bnz(2))] undergoes facile conversion to the dimeric complex, [Re(CO)(3)(HBnz(2))](2), via bromide dissociation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23168308     DOI: 10.1016/j.jinorgbio.2012.10.011

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  5 in total

1.  The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers.

Authors:  Philippe Collery; Vijay Veena; Adhikesavan Harikrishnan; Didier Desmaele
Journal:  Invest New Drugs       Date:  2019-01-11       Impact factor: 3.850

2.  Enhanced Cytotoxicity through Conjugation of a "Clickable" Luminescent Re(I) Complex to a Cell-Penetrating Lipopeptide.

Authors:  Anna Leonidova; Vanessa Pierroz; Luke A Adams; Nicholas Barlow; Stefano Ferrari; Bim Graham; Gilles Gasser
Journal:  ACS Med Chem Lett       Date:  2014-05-15       Impact factor: 4.345

3.  The effect of novel rhenium compounds on lymphosarcoma, PC-3 prostate and myeloid leukemia cancer cell lines and an investigation on the DNA binding properties of one of these compounds through electronic spectroscopy.

Authors:  Carl Parson; Valerie Smith; Christopher Krauss; Hirendra N Banerjee; Christopher Reilly; Jeanette A Krause; James M Wachira; Dipak Giri; Angela Winstead; Santosh K Mandal
Journal:  J Bioprocess Biotech       Date:  2013-12-27

4.  Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer.

Authors:  Philippe Collery; Ahmed Mohsen; Anthony Kermagoret; Samantha Corre; Gérard Bastian; Alain Tomas; Ming Wei; François Santoni; Nadia Guerra; Didier Desmaële; Jean d'Angelo
Journal:  Invest New Drugs       Date:  2015-06-26       Impact factor: 3.850

5.  Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents.

Authors:  Anne Cecília Nascimento da Cruz; Dalci José Brondani; Temístocles I Talo de Santana; Lucas Oliveira da Silva; Elizabeth Fernanda da Oliveira Borba; Antônio Rodolfo de Faria; Julianna Ferreira Cavalcanti de Albuquerque; Sylvie Piessard; Rafael Matos Ximenes; Blandine Baratte; Stéphane Bach; Sandrine Ruchaud; Francisco Jaime Bezerra Mendonça Junior; Marc-Antoine Bazin; Marcelo Montenegro Rabello; Marcelo Zaldini Hernandes; Pascal Marchand; Teresinha Gonçalves da Silva
Journal:  Pharmaceuticals (Basel)       Date:  2019-11-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.